Patrick Neven, MD, PhD

Videos

Safety, Tolerability of Capivasertib Plus Palbociclib and Fulvestrant Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

02/05/2024

Patrick Neven , MD, PhD;

Patrick Neven, MD, PhD, discusses updated phase 1b results from the CAPItello-292 study which demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive,...

Patrick Neven, MD, PhD,...

02/05/2024

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Patrick Neven, MD, PhD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products